Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13868638 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL13359968 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL14982786 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL5713241 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL614427 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL13572033 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL16349763 | 0.74 | PDE4A (0.56) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL1701008 | 0.73 | KDM4E (0.43) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| SCHEMBL28260109 | 0.73 | PDE4A (0.50) | PDE4ALMNAKDM4EL3MBTL1TDP1 | |
| Ammonia Solution, Strong SCHEMBL27853962 | 0.72 | PDE4A (0.54) | PDE4ALMNAKDM4EL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005027873-A2 | THERAPEUTIC AMINOGLYCOSIDE-CONTAINING HYDROGEL NANOPARTICLES | ALNIS BIOSCIENCES, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040126900-A1 | High affinity peptide- containing nanoparticles | ALNIS BIOSCIENCES INC. | 2004-07-01 | — | — | US | disclosed |
| EP-1276507-A2 | HIGH AFFINITY PEPTIDE-CONTAINING NANOPARTICLES | Alnis Biosciences, Inc. (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001078786-A2 | HIGH AFFINITY PEPTIDE-CONTAINING NANOPARTICLES | ALNIS BIOSCIENCES, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040126900-A1 | High affinity peptide- containing nanoparticles | LNPEP, IAPP, ACP1 | PDE4A 4437/4885LMNA 2517/4885KDM4E 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.